Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HRH1 | P35367 | 2/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724788 | 0.89 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485675 | 0.89 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL3048356 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485667 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL725483 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL2845851 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL8658187 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL29485634 | 0.87 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 | |
| SCHEMBL1592572 | 0.85 | — | — | |
| SCHEMBL2843094 | 0.85 | CYP2A6 (0.76) | TDP1L3MBTL1HRH1CYP2A6TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900214-B2 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-31 | — | — | US | claimed |
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | claimed |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143026-A1 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | CCNB1, BUB1B, BUB1 | TDP1 312/4885L3MBTL1 1533/4885HRH1 1764/4885 |
| US-20050014810-A1 | Use of substituted 2 phenylbenzimidazoles as medicaments | GLP1R, GIPR, GCGR | TDP1 4057/4885L3MBTL1 1957/4885HRH1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.